Definition and Clinical Context
Massive transfusion (MT) is defined as the administration of greater than 10 units of red blood cells (RBCs) within 24 hours after initiating treatment. Alternative definitions applicable in the acute setting include:
- ≥4 units RBC within 1 hour when ongoing need is foreseeable
- Replacement of ≥50% of total blood volume within 3 hours
MT occurs in approximately 10% of military trauma and 5% of civilian trauma patients. Patients receiving >10 units RBC within 6 hours carry higher mortality; however, MT itself is likely a marker of injury severity rather than a direct cause of death. The development and implementation of MT protocols has significantly improved survival across trauma, surgical, and obstetric settings.
Pathophysiology: The Lethal Triad and Beyond
The Lethal Triad
The triad of coagulopathy, hypothermia, and acidosis represents the cornerstone of pathophysiology driving mortality in massive haemorrhage. These three elements are mutually reinforcing:
| Component | Mechanism | Consequence |
|---|---|---|
| Coagulopathy | Dilution, consumption, fibrinolysis, DIC | Uncontrolled bleeding |
| Hypothermia | Enzyme dysfunction, platelet dysfunction | Impaired clot formation |
| Acidosis | Inhibits coagulation factor activity, hypocalcaemia | Compound coagulopathy |
Endotheliopathy of Trauma
Haemorrhagic shock causes systemic endothelial injury - endotheliopathy of trauma - leading to: - Coagulopathy - Systemic inflammation and vascular permeability - Tissue oedema - Multiorgan dysfunction
Mechanisms of Coagulopathy
1. Dilutional Coagulopathy Resuscitation with crystalloids, colloids, and RBCs dilutes coagulation factors and platelets. Historically, transfusion of 15-20 units of stored whole blood caused platelet counts to fall to 20,000-30,000/mm³, far below the recommended threshold for actively bleeding patients.
2. Fibrinolysis Tissue injury activates tissue plasminogen activator (tPA), converting plasminogen to plasmin. Plasmin: - Degrades fibrinogen and von Willebrand factor (vWF) - Cleaves glycoprotein Ib from platelets - Generates fibrin degradation products (FDPs) that bind glycoprotein IIb/IIIa, preventing platelet-fibrinogen crosslinking - Causes proinflammatory effects including complement activation and neutrophil chemotaxis
Physiologically, fibrinolysis is regulated by PAI-1, $\alpha_2$-antiplasmin, and TAFI - all of which are depleted during massive haemorrhage. The result is pathological hyperfibrinolysis.
3. Hypofibrinogenaemia Fibrinogen is the coagulation factor present at the highest plasma concentration (normal: 200-400 mg/dL). It is the first factor to fall critically during massive haemorrhage. When fibrinogen falls to approximately 80-100 mg/dL, standard clotting tests (PT, PTT) are significantly prolonged and may be irreversible with FFP alone.
4. Acidaemia Acidosis impairs coagulation factor enzyme function and may induce hypocalcaemia - calcium being essential for multiple steps in the coagulation cascade.
5. Crystalloid-Associated Harm Crystalloids lack the serine protease inhibitors present in plasma (antithrombin III, C1 esterase inhibitor, TFPI, PAI-1, $\alpha_2$-antiplasmin). Large crystalloid volumes increase interstitial oedema, worsen lung injury, and promote multiorgan dysfunction. Large crystalloid resuscitation is associated with increased bleeding and lower survival in trauma.
Massive Transfusion Protocol (MTP)
Activation Criteria and Initial Steps
An MTP should be activated early, based on clinical judgement, not solely laboratory values. Activation triggers include:
| Criterion | Detail |
|---|---|
| Anticipated MT | Clinical assessment of ongoing haemorrhage requiring >10 units RBC |
| Haemodynamic instability | Refractory to initial resuscitation |
| Specific scores | Shock index, ABC score, clinical gestalt |
Immediate steps on MTP activation: 1. Notify transfusion laboratory - prepare blood components 2. Notify haematologist/transfusion specialist 3. Baseline investigations: FBC, coagulation screen (PT, INR, aPTT, fibrinogen), biochemistry (including ionised calcium), arterial blood gas 4. Repeat testing every 30-60 minutes during active resuscitation 5. Optimise: oxygenation, cardiac output, tissue perfusion, metabolic state
Component Therapy Ratios
Observational and retrospective data (initially from military trauma) support the administration of blood products in a 1:1:1 ratio of RBCs:FFP:platelets - mimicking whole blood:
| Component | Target Ratio | Notes |
|---|---|---|
| RBC | 1 | Oxygen-carrying capacity; haemostatic role via ADP release |
| FFP/Plasma | 1 | Contains all coagulation factors and serine protease inhibitors |
| Platelets | 1 (adult therapeutic dose) | Target platelet count ≥50,000/mm³ in active bleeding |
The optimal FFP:RBC ratio is not definitively established from prospective data, though retrospective data support ≥1:1 ratios. Fresh whole blood remains the ideal resuscitation fluid in haemorrhagic shock but is not widely available in civilian settings.
Fibrinogen Replacement
Fibrinogen is a critical therapeutic target. Treatment is indicated when fibrinogen falls below 1.0 g/L:
| Product | Indication | Dose |
|---|---|---|
| Cryoprecipitate | Fibrinogen < 1.0 g/L | 3-4 g (approximately 10 units) |
| Fibrinogen concentrate | Available in some countries (e.g. Europe) where cryoprecipitate unavailable | Goal-directed based on ROTEM/TEG |
European guidelines using ROTEM-guided therapy utilise fibrinogen concentrate, prothrombin complex concentrate (PCC), and factor XIII based on viscoelastic testing. In countries where cryoprecipitate is not available, fibrinogen concentrate is the standard replacement.
FFP Dosing
| Indication | Dose |
|---|---|
| INR > 1.5 with active bleeding | 15 mL/kg FFP |
Prevention and Management of Specific Complications
1. Hypothermia
Hypothermia is both a consequence and a driver of coagulopathy. Prevention is essential:
| Strategy | Details |
|---|---|
| Warming of all IV fluids and blood products | Blood warmers in all high-volume infusion circuits |
| Active patient warming | Forced-air warming, warm theatre environment |
| Minimise exposure | Limit heat loss from open body cavities |
2. Acidosis
Addressing the underlying cause (haemorrhage control, restoring perfusion) is primary. Adjuncts include: - THAM (tris-hydroxymethyl aminomethane): alternative alkalising agent to sodium bicarbonate - Correction of hypocalcaemia - Avoiding worsening acidosis from large crystalloid loads (hyperchloraemic acidosis)
3. Hypocalcaemia
Citrate in stored blood products chelates ionised calcium. With high-volume transfusion, ionised hypocalcaemia develops and impairs myocardial function and coagulation. Calcium supplementation should be empirical during MT:
- Monitor ionised calcium regularly (target > 1.1 mmol/L)
- Replace with calcium chloride or calcium gluconate as appropriate
4. Dilutional Coagulopathy
Prevented by early, proactive use of plasma and platelet-containing products rather than crystalloids. Avoid the historical approach of replacing early blood loss with crystalloids and then treating coagulopathy reactively.
5. Hyperfibrinolysis
Antifibrinolytic therapy is a critical component of multimodal management:
| Agent | Dose | Notes |
|---|---|---|
| Tranexamic acid (TXA) | 1 g IV over 10 min loading dose, then 1 g IV over 8 hours | Approved in trauma; most evidence base; available in Europe and Australasia |
| Epsilon-aminocaproic acid | Alternative lysine analogue | Less studied than TXA; not available in all countries |
TXA inhibits the conversion of plasminogen to plasmin, preserving fibrin clot integrity at the bleeding site. It is most effective when administered early.
6. Transfusion-Related Complications
| Complication | Features | Prevention/Management |
|---|---|---|
| TRALI | Acute hypoxia, bilateral infiltrates within 6 h of transfusion | Male-predominant plasma strategy; supportive care |
| TACO | Pulmonary oedema, hypertension, fluid overload | Judicious transfusion; diuretics |
| Haemolytic transfusion reaction | ABO incompatibility; fever, haemolysis, renal failure | ABO verification; stop transfusion; supportive care |
| Anaphylaxis | IgA deficiency, other allergens | Recognition; adrenaline; IgA-deficient products if known |
| Hyperkalaemia | Stored RBCs release potassium | Monitor electrolytes; use fresher blood if available |
| Hypothermia | Cold stored products | Blood warmers |
| Citrate toxicity/hypocalcaemia | Chelation of ionised Ca²⁺ | Calcium supplementation |
Monitoring Haemostasis During Massive Transfusion
Standard Tests
| Test | Normal Range | Role and Limitations |
|---|---|---|
| PT/INR | PT: 11-14 s | Reflects extrinsic/common pathway; proportional to factor loss; slow turnaround |
| aPTT | 25-38 s | Intrinsic/common pathway; best single screening test; slow |
| Fibrinogen | 200-400 mg/dL | Critical target; must be monitored serially |
| FBC (platelet count) | Target >50,000/mm³ in active bleeding | Dilutional thrombocytopenia common |
| Ionised calcium | Target >1.1 mmol/L | Essential to monitor |
Standard coagulation tests have significant limitations during MT: they are slow, do not assess platelet function or factor-platelet interactions, and may be prolonged by protein C deficiency independent of clotting factor levels.
Viscoelastic Testing (TEG/ROTEM)
Point-of-care viscoelastic testing - thromboelastography (TEG) and thromboelastometry (ROTEM) - has become the focus of most goal-directed transfusion algorithms:
| Parameter | TEG | ROTEM | Significance |
|---|---|---|---|
| Clot formation | R time | CT | Factor deficiency |
| Clot kinetics | K time, alpha angle | CFT, alpha angle | Fibrinogen function |
| Clot strength | MA (maximal amplitude) | MCF (maximal clot firmness) | Platelets + fibrinogen |
| Fibrinogen contribution | - | FIBTEM MCF | Isolated fibrinogen assessment |
| Fibrinolysis | LY30 | ML (maximum lysis) | Identifies hyperfibrinolysis |
ROTEM FIBTEM assay allows rapid determination of systemic fibrinogen levels and guides targeted fibrinogen replacement. Goal-directed algorithms using viscoelastic testing reduce unnecessary transfusion and guide component selection.
Perioperative Management
Damage Control Resuscitation (DCR)
DCR is the overarching multimodal strategy derived from military experience, incorporating:
| Principle | Strategy |
|---|---|
| Haemostatic resuscitation | Early 1:1:1 ratio RBC:FFP:platelets; minimise crystalloid |
| Permissive hypotension | Avoid aggressive BP normalisation until surgical haemostasis achieved (in penetrating trauma) |
| Avoid the lethal triad | Warming, calcium replacement, correct acidosis |
| Antifibrinolytic therapy | Early TXA |
| Adjunct pharmacotherapy | Calcium, THAM, off-label procoagulants |
| Early definitive haemostasis | Surgical or interventional control of bleeding source |
Crystalloid Restriction
The paradigm shift in MT management is clear: crystalloids are no longer a primary resuscitation fluid. Replace acute blood loss with plasma and platelet-containing products. Large crystalloid volumes are associated with increased bleeding, interstitial oedema, pulmonary injury, and worse survival.
Fibrinogen as a Priority Target
Evaluating and replacing fibrinogen is a critical and often underappreciated component of every transfusion algorithm. Serial monitoring and early replacement (cryoprecipitate or fibrinogen concentrate) targeting levels >1.5-2.0 g/L should be prioritised.
Special Populations
Obstetric haemorrhage: Severe postpartum haemorrhage (>1,000 mL within 24 hours despite first-line uterotonics) requires early MTP activation with haemostatic resuscitation. Coagulation testing should guide therapy. Surgical options (balloon tamponade, brace sutures, hysterectomy) are escalated alongside pharmacological measures including TXA. Note: in late pregnancy, fibrinogen is physiologically elevated (400-600 mg/dL), so a level of 200 mg/dL - normal in non-pregnant patients - may represent relative hypofibrinogenaemia in this context.
Consultant Decision Framework
As the consultant anaesthetist managing a massive haemorrhage:
- Activate MTP early - do not wait for laboratory confirmation
- Communicate with the surgical team, blood bank, and haematologist
- Parallel preparation - ensure adequate IV access, arterial line, monitoring
- Drive haemostatic resuscitation - 1:1:1 ratio, early TXA, fibrinogen replacement
- Correct the lethal triad - warm all products, treat acidosis, give calcium
- Transition to goal-directed therapy - use TEG/ROTEM to guide ongoing component therapy and reduce unnecessary transfusion
- Monitor for transfusion complications - TRALI, TACO, hyperkalaemia, hypocalcaemia
- Cease MTP once bleeding is controlled; notify transfusion laboratory
The multispecialty, protocol-driven approach - incorporating surgeons, anaesthetists, emergency physicians, and transfusion medicine specialists - represents the current standard of care and is associated with improved survival outcomes.